Drugmaker offers view on UK's new medicines fund as consultation launched

22 November 2021

The National Institute of Health and Care Excellence (NICE) and the National Health Service (NHS) England have launched a consultation on the Innovative Medicines Fund (IMF).

Although similar to the Cancer Drugs Fund (CDF), the IMF is also able to help people needing non-cancer medicines, particularly those suffering from rare diseases, to access innovative treatments earlier, when further real-world data may still be needed in order for the treatment to be approved for use on the NHS.

"The potential to benefit many more people in the UK in desperate need of new treatments"NHS England announced the creation of the IMF in July and, following its launch last week, the consultation will continue until February 11.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK